Story · Health Tech · Products

Pfizer’s Immunology Strategy Expands to In Vivo Cell Therapy With Starna Deal

1 outlet · first reported by MedCity News on

Pfizer gains global rights, excluding Greater China, to three in vivo CAR-T cell therapies from Starna Therapeutics in preclinical development for undisclosed autoimmune diseases. It’s the latest in a series of big pharma business deals involving in vivo cell therapy assets and platform… (MedCity News)

Coverage, in order

  1. MedCity News indie
    Pfizer’s Immunology Strategy Expands to In Vivo Cell Therapy With Starna Deal

    Pfizer gains global rights, excluding Greater China, to three in vivo CAR-T cell therapies from Starna Therapeutics in preclinical development for undisclosed autoimmune diseases. It’s the latest in a series of big pharma business deals involving in vivo cell therapy assets and platform…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.